Invus is an evergreen equity investment firm that focuses on empowering owner-managers to transform their industries through a long-term investment horizon. The firm invests across a broad range of sectors, including biotech, AI/ML, FinTech, consumer goods, and software, aiming for sustainable value creation by providing capital, strategic advice, and the freedom to take risks.
59% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $96.7M (across 47 rounds with reported amounts).
Portfolio
51
Fund Size
$10B
Top Stage
Series B
Last 12 Mo
7
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
51 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Bambusa Therapeutics | Series A | — | Nov 2025 |
 Artios Pharma Limited | Series D | $115M | Nov 2025 |
| RRani Therapeutics | Series C | $60.3M | Oct 2025 |
 Veradermics | Series C | $150M | Oct 2025 |
 One Biosciences | Series A | $15M | Jul 2025 |
| AAive | Series A | $12M | Jun 2025 |
| Bambusa Therapeutics | Series A | $90M | Feb 2025 |
 Coave Therapeutics | Series A | $33M | Jan 2025 |
 Ottimo Pharma | Series A | $140M | Dec 2024 |
 Noema Pharma | Series B | — | Dec 2024 |
 PrognomiQ | Series D | $34M | Nov 2024 |
| IInventiva | Unknown | $410M | Oct 2024 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
| KKNIME | Unknown | $30M | Aug 2024 |
| EExsilio Therapeutics | Series A | $82M | Jun 2024 |
 Lycia Therapeutics, Inc. | Series C | $106.6M | May 2024 |
| Triveni Bio Inc. | Series A | $92M | Oct 2023 |
 PayJoy | Series C | $150M | Sep 2023 |
 Convergent Therapeutics Inc. | Series A | $90M | May 2023 |
 Flare Therapeutics Inc. | Series B | $123M | Mar 2023 |
 Rain | Series B | $66M | Mar 2023 |
 Hemab Therapeutics | Series B | $135M | Feb 2023 |
 Leyden Laboratories B.V. | Series B | $140M | Jan 2022 |
 Klarity | Series A | $18M | Jan 2022 |
Page 1 of 3
Top Co-Investors
RA Capital Management9 shared
OrbiMed7 shared
Redmile Group6 shared
Polaris Venture Partners6 shared
Novartis Venture Fund5 shared
Sofinnova Partners5 shared
QED Investors4 shared
Pfizer Ventures4 shared
Janus Henderson Investors4 shared
Deep Track Capital4 shared
RTW Investments3 shared
Casdin Capital3 shared
Atlas Venture3 shared
Cormorant Asset Management3 shared
GV (Google Ventures)3 shared
NEA (New Enterprise Associates)3 shared
Andera Partners3 shared
Perceptive Advisors3 shared
Avidity Partners3 shared
Alexandria Venture Investments3 shared
Last updated: 16 April 2026